Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Kinetensin acetate(103131-69-7 free base)

🥰Excellent
Catalog No. TP1116L
Alias Kinetensin (human) acetate

Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide.

Kinetensin acetate(103131-69-7 free base)

Kinetensin acetate(103131-69-7 free base)

🥰Excellent
Catalog No. TP1116LAlias Kinetensin (human) acetate
Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$96In StockIn Stock
5 mg$188In StockIn Stock
10 mg$307In StockIn Stock
25 mg$540In StockIn Stock
50 mg$779In StockIn Stock
100 mg$1,090In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:>99.99%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide.
In vitro
The peptide kinetensin isolated from pepsin-treated human plasma induces a dose-dependent release of histamine when exposed to rat peritoneal mast cells. The threshold concentration is around 1 μM, the ED50 is 10 μM, and the optimal concentration of between 100 to 1000 μM released 80% of the total histamine. Kinetensin is 10 to 100 times less potent than neurotensin and equipotent with the opioid peptide dynorphin. The histamine release is clearly temperature-dependent, with no release occurring at 0 or 45 °C and with an optimum around 37 °C. The histamine release is significantly reduced in the absence of extracellular calcium[2].
In vivo
Kinetensin also induces a dose-dependent increase in vascular permeability when injected intradermally into rats[2].
SynonymsKinetensin (human) acetate
Chemical Properties
Molecular Weight1232.45
FormulaC58H89N17O13
SmilesCC[C@H](C)[C@H](N)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CN=CN1)C(N2[C@@H](CCC2)C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC(C)C)=O)CC3=CC=CC=C3)=O)CC4=CC=C(C=C4)O)=O)=O)=O)=O)=O)=O.CC(O)=O
Relative Density.no data available
SequenceIle-Ala-Arg-Arg-His-Pro-Tyr-Phe-Leu
Sequence ShortIARRHPYFL
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 10 mM, Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM0.8114 mL4.0570 mL8.1139 mL40.5696 mL
5 mM0.1623 mL0.8114 mL1.6228 mL8.1139 mL
10 mM0.0811 mL0.4057 mL0.8114 mL4.0570 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Kinetensin acetate(103131-69-7 free base) | purchase Kinetensin acetate(103131-69-7 free base) | Kinetensin acetate(103131-69-7 free base) cost | order Kinetensin acetate(103131-69-7 free base) | Kinetensin acetate(103131-69-7 free base) chemical structure | Kinetensin acetate(103131-69-7 free base) in vivo | Kinetensin acetate(103131-69-7 free base) in vitro | Kinetensin acetate(103131-69-7 free base) formula | Kinetensin acetate(103131-69-7 free base) molecular weight